Table 5 Summary of main genomic alterations detected by Array-based Comparative Genomic Hybridization.

From: NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker

Case

Genomic index

Homozygous loss (gene)

Gain (gene)

Fusion gene breakpoints (genomic coordinatesa)

Other findings

Case 1

28.8

7; 8; 20q13.12; 20q13.13-13.2; 22q11.1-q12.1; 22q12.1-q12.2

- NFATc2 (20:50,112,183-50,157,437)

- EWSR1: (22:29,673,668-29,682,794)

-Heterozygous loss of 9q

Case 2

62.5

9p21.3 (CDKN2A/CDKN2B); interstitial loss of Xp21 (DMD); 3q13.31 (TUSC7)

3q13.31-qter; 4q; 8; 20p; 20q11.21-q13.2 (including NFATc2); 16p13.3-p11.2 (including FUS)

- NFATc2 (20:50,112,183-50,157,437)

- FUS (16:31,196,228-31,227,791)

Case 3

344

2p12 (including CTNNA2); 9p21.3 (CDKN2A/CDKN2B); Xp21.2; Xp11.4-p11.3; Xq21.33-q28; Xp22.33-p22.2; 3q13.31 (TUSC7)

8q21.11; 12p13.33-p13.1; 12q15 (including MDM2)

- NFATc2 (20:50,007,988-50,157,437)

-Heterozygous loss of Xp21 (including DMD)

Case 4

103

9p24.3; 9p21.3-p21.1; 9p21.3 (CDKN2A/CDKN2B); 14q21.2; Xq23

8p11.21-p11.1; 8q11.1-q24.3; 9p24.3-p22.2 (including SMARCA2); 18q12.1 (including CDH2);

Heterozygous loss of 3q13.31 (TUSC7)

  1. aBased on Genome Reference Consortium Human Build 37.